|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 1.060 USD | +2.91% |
|
+3.92% | -21.48% |
| 09-14 | Ocugen Insider Sold Shares Worth $589,110, According to a Recent SEC Filing | MT |
| 09-01 | Ocugen Doses First Patient in Trial of Potential Eye Disease Drug | MT |
Company Valuation: Ocugen, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 906.3 | 284.6 | 147.5 | 234.5 | 421.6 | 359.5 | - | - |
| Change | - | -68.6% | -48.17% | 59% | 79.79% | -14.75% | - | - |
| Enterprise Value (EV) | 906.3 | 284.6 | 147.5 | 234.5 | 421.6 | 359.5 | 359.5 | 359.5 |
| Change | - | -68.6% | -48.17% | 59% | 79.79% | -14.75% | 0% | 0% |
| P/E | -15.2x | -3.42x | -2.21x | -4.03x | -5.87x | -4.08x | -3.79x | -28.3x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.1x | 0.2x | -0.4x | -0.3x | -0.49x | 0.3x |
| Capitalization / Revenue | - | - | 24.4x | 57.8x | 95.5x | 75.6x | 144x | 2.52x |
| EV / Revenue | - | - | 0x | 0x | 0x | 75.6x | 144x | 2.52x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -4.96x | -4.09x | -72.3x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.38 | -0.26 | -0.2 | -0.23 | -0.26 | -0.28 | -0.0375 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | 6.036 | 4.055 | 4.413 | 4.757 | 2.5 | 142.6 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -58.03 | -84.87 | -65.53 | -54.76 | -62.92 | -72.48 | -87.98 | -4.973 |
| Net income 1 | -58.36 | -81.35 | -63.08 | -54.05 | -67.85 | -87.21 | -97.94 | -14.95 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 4.550 | 1.300 | 0.575 | 0.805 | 1.350 | 1.060 | 1.060 | 1.060 |
| Nbr of stocks (in thousands) | 199,186 | 218,887 | 256,502 | 291,320 | 312,320 | 339,110 | - | - |
| Announcement Date | 2/25/22 | 2/28/23 | 4/16/24 | 3/5/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.08x | - | - | - | 359M | |
| 31.88x | 5.74x | 17.19x | 1.02% | 46.28B | |
| 34.31x | 3.31x | 14.29x | -.--% | 43.85B | |
| -19.53x | 224.63x | -20.86x | -.--% | 40.93B | |
| 45.96x | 5.31x | 29.04x | -.--% | 39.89B | |
| 27.09x | 7.81x | 19.95x | 0.42% | 29.5B | |
| 34.82x | 5.71x | 25.95x | -.--% | 17.09B | |
| 25.48x | 2.19x | 9.51x | 1.05% | 15.22B | |
| -55.89x | 9.19x | 224.28x | -.--% | 14.05B | |
| Average | 13.34x | 32.99x | 39.92x | 0.31% | 27.46B | |
| Weighted average by Cap. | 20.27x | 41.76x | 24.53x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OCGN Stock
- Valuation Ocugen, Inc.
Select your edition
All financial news and data tailored to specific country editions
